| Sawyer Lee, | |
|
2008 S Post Rd, Midwest City, OK 73130-6610 | |
| (405) 732-2277 | |
| (407) 737-4776 |
| Full Name | Sawyer Lee |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 4 Years |
| Location | 2008 S Post Rd, Midwest City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144848177 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 3083 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-del Vision Source, Pllc | 3274768239 | 9 |
News Archive
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
They worked in hospitals hundreds of miles from the epicenter of COVID-19. Their city of 24 million people locked down hard enough, and did enough testing, that it only had a few hundred cases of the disease.
A redesigned version of the CTC-Chip a microchip-based device for capturing rare circulating tumor cells (CTCs) appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells.
A major discovery, led by researchers from The George Washington University Medical Center, promises to revolutionize the way scientists think about key aspects of cellular lifecycle and offers a new avenue for cancer researchers to explore in their quest to one day slow down the progression of cancer.
› Verified 7 days ago
| Provider Name | Mid-del Vision Source, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1982940508 PECOS PAC ID: 3274768239 Enrollment ID: O20131113001833 |
News Archive
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
They worked in hospitals hundreds of miles from the epicenter of COVID-19. Their city of 24 million people locked down hard enough, and did enough testing, that it only had a few hundred cases of the disease.
A redesigned version of the CTC-Chip a microchip-based device for capturing rare circulating tumor cells (CTCs) appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells.
A major discovery, led by researchers from The George Washington University Medical Center, promises to revolutionize the way scientists think about key aspects of cellular lifecycle and offers a new avenue for cancer researchers to explore in their quest to one day slow down the progression of cancer.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sawyer Lee, 2008 S Post Rd, Midwest City, OK 73130-6610 Ph: (405) 732-2244 | Sawyer Lee, 2008 S Post Rd, Midwest City, OK 73130-6610 Ph: (405) 732-2277 |
News Archive
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), announced today that it has entered into a research collaboration with Mirna Therapeutics (Austin, TX), to determine the utility of combining RXi's proprietary rxRNA™ technology with Mirna's microRNA mimics as potential therapeutics in oncology. The parties will each contribute technology and resources to the collaboration to generate and evaluate novel microRNA compounds.
A research team led by Arun Iyer, Ph.D., assistant professor of pharmaceutical sciences in the Eugene Applebaum College of Pharmacy and Health Sciences at Wayne State University, has developed a nanoplatform technology that works in combination with existing chemotherapeutic drugs that may reverse drug-resistance in renal cell carcinoma.
They worked in hospitals hundreds of miles from the epicenter of COVID-19. Their city of 24 million people locked down hard enough, and did enough testing, that it only had a few hundred cases of the disease.
A redesigned version of the CTC-Chip a microchip-based device for capturing rare circulating tumor cells (CTCs) appears to be more effective and should be easier to manufacture than the original. Called the HB-(herringbone) Chip, the new device also may provide more comprehensive and easily accessible data from captured tumor cells.
A major discovery, led by researchers from The George Washington University Medical Center, promises to revolutionize the way scientists think about key aspects of cellular lifecycle and offers a new avenue for cancer researchers to explore in their quest to one day slow down the progression of cancer.
› Verified 7 days ago
Dr. Kathleen Yang, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8121 National Ave, Suite 409, Midwest City, OK 73110 Phone: 405-737-8935 Fax: 405-737-8934 | |
Midwest City Eye Care Associates Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 8121 National Ave, Suite 409, Midwest City, OK 73110 Phone: 405-737-8935 Fax: 405-737-8934 | |
Bob Baldwin, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6912 E Reno Ave, Suite 101, Midwest City, OK 73110 Phone: 405-732-2277 Fax: 405-737-4776 | |
Dr. Megan Rae Tucker, OD Optometrist Medicare: Medicare Enrolled Practice Location: 1200 S Air Depot Blvd Ste A, Midwest City, OK 73110 Phone: 405-494-8100 | |
Dr. Elizabeth Mccrackin, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2008 S Post Rd, Midwest City, OK 73130 Phone: 405-732-2277 Fax: 405-737-4776 | |
Midwest Vision Center Optometrist Medicare: Medicare Enrolled Practice Location: 1029 S Post Rd, Midwest City, OK 73130 Phone: 405-737-0713 Fax: 405-732-2225 |